<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2008, p. 3710&#226;&#8364;&#8220;3717                                                                   Vol. 52, No. 10 <br /> 0066-4804/08/$08.00&#226;&#171;&#185;0 doi:10.1128/AAC.00364-08 <br /> Copyright &#194;&#169; 2008, American Society Microbiology. All Rights Reserved. <br />  <br />  <br />  <br />     Glycogen Synthase Kinase 3 Is Potential Drug Target African <br />                        Trypanosomiasis Therapy&#228;&#338;&#164; <br />   Kayode K. Ojo,1 J. Robert Gillespie,1 Aaron J. Riechers,1 Alberto J. Napuli,2 Christophe L. M. J. Verlinde,2 <br />         Frederick S. Buckner,1 Michael H. Gelb,3 Mathias M. Domostoj,4 Susan J. Wells,4 <br />                Alexander Scheer,4 Timothy N. C. Wells,4 Wesley C. Van Voorhis1* <br />   Division Allergy Infectious Diseases, Department Medicine,1 Department Biochemistry,2 Department Chemistry,3 <br />                   University Washington, Seattle, Washington 98195, Merck-Serono Geneva Research Centre, <br />                         Merck-Serono International S.A. Chemin des Mines 9, Geneva CH-1202, Switzerland4 <br />                            Received 16 March 2008/Returned modification 26 May 2008/Accepted 10 July 2008 <br />  <br />             Development safe, effective, inexpensive therapy African trypanosomiasis urgent priority. <br />           In study, evaluated validity Trypanosoma brucei glycogen synthase kinase 3 (GSK-3) potential <br />           drug target. Interference RNA of GSK-3 homologues bloodstream-form T. brucei <br />           parasites led growth arrest altered parasite morphology, demonstrating requirement cell <br />           <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-77' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span>survival</span>. Since growth arrest <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-207' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-213' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-216' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-228' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span>RNA interference</span> appeared profound T. brucei GSK-3 <br />           &#226;&#8364;&#339;short&#226;&#8364;? (Tb10.161.3140) T. brucei GSK-3 &#226;&#8364;&#339;long&#226;&#8364;? (Tb927.7.2420), focused T. brucei GSK-3 short <br />           studies. T. brucei GSK-3 short N-terminal maltose-binding protein fusion cloned, <br />           expressed, purified functional form. The potency GSK-3-focused inhibitor library the <br />           recombinant enzyme T. brucei GSK-3 short, bloodstream-form parasites, evaluated the <br />           aim determining compounds inhibit enzyme activity block parasites&#226;&#8364;&#8482; growth and <br />           proliferation. Among compounds active cell, excellent correlation activity <br />           inhibiting T. brucei GSK-3 short enzyme inhibition T. brucei growth. Thus, reasonable <br />           genetic chemical validation GSK-3 short drug target T. brucei. Finally, selective inhibition may <br />           required therapy targeting GSK-3 enzyme, molecular model T. brucei GSK-3 short <br />           enzyme suggests compounds selectively inhibit T. brucei GSK-3 short human GSK-3 enzymes <br />           found. <br />  <br />  <br />    The vector-borne parasitic disease African trypanosomiasis,                  protein degradation machinery. Many kinases ex- <br /> caused members Trypanosoma brucei complex,                       amined physiological relevance phosphoryla- <br /> serious health threat. It estimated 300,000 500,000                  tion activities organisms, glycogen synthase kinase <br /> humans sub-Saharan African infected. If disease                   3 (GSK-3) essential fundamental <br /> left inadequately treated, fatal outcome (9). Once               cellular processes (22, 30). <br /> infection established, safe effective therapy critically                 Far simply important glycogen synthesis, the <br /> important, difficult achieve. Despite                    activity GSK-3 recognized key mammalian cell <br /> critical need, available therapies satis-                 signaling pathways cellular physiological events <br /> factory rising level resistance available                  (26). GSK-3 targeted treatment several <br /> drugs, long period treatment required achieve cure,                 diseases, diabetes mellitus Alzheimer&#226;&#8364;&#8482;s dementia, <br /> and unacceptable severe adverse effects                       enzyme amenable selective <br /> associated current therapies (9). An urgent priority                 targeting small-molecule drugs (22). GSK-3 iso- <br /> identify validate new targets development safe,                  forms human cells, GSK-3&#226;?&#163; GSK-3&#226;?&#164;. The GSK-3&#226;?&#163; and <br /> effective, inexpensive therapeutic alternatives.                            GSK-3&#226;?&#164; isoforms rarely diverge outside N- C-terminal <br />    Recent advances area parasite genomics bio-                    regions. Within ATP binding site GSK-3, most <br /> chemical investigation physiologically important en-                     GSK-3 inhibitors bind, appears single amino <br /> zymes necessary parasite&#226;&#8364;&#8482;s survival identified pro-                acid difference (Glu196 GSK-3&#226;?&#163;, Asp133 GSK-3&#226;?&#164;), and <br /> tein kinases potential drug targets treatments                        inhibitors target isoforms. GSK-3 generally requires <br /> trypanosomatid diseases (3, 14, 23). Protein kinases play                    substrate prephosphorylated priming kinase (6, 7, <br /> important role <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-131' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-133' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-137' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-142' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-152' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-157' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span>cell survival</span> phosphorylating regulat-                 10, 32) (Fig. 1), leading role signaling cascades. GSK-3 <br /> ing activities cell, including protein synthesis, gene              regulated autophosphorylation phosphorylation by <br /> expression, subcellular localization proteins,                   enzymes. <br />                                                                                    Even orthologs exhibit high degree sequence <br />                                                                                 similarity catalytic domains (7, 22), exists <br />   * Corresponding author. Mailing address: Division Allergy              evolutionary differences human parasite homo- <br /> Infectious Diseases, Department Medicine, Box 357185, 1959 NE <br /> Pacific St., Seattle, WA 98195-7185. Phone: (206) 543-2447. Fax: (206) <br />                                                                                 logues sufficient allow design parasite- <br /> 685-8681. E-mail: wesley@u.washington.edu.                                      specific inhibitors. Compounds inhibit T. brucei GSK-3 <br />   &#228;&#338;&#164; <br />     Published ahead print 21 July 2008.                                   activity host GSK-3 required therapy for <br />  <br />                                                                          3710 <br />  VOL. 52, 2008                                                              GSK-3: DRUG TARGET FOR AFRICAN TRYPANOSOMIASIS                                        3711 <br />  <br />                                                                                      knock longer isoform. The regions T. brucei GSK-3 short and <br />                                                                                      long gene-coding sequences selected RNAi plasmid construction de- <br />                                                                                      termined using RNA target selection program RNAit (29), ensure that <br />                                                                                      significant sequence homology genes genome. <br />                                                                                      The sequences T. brucei genomic DNA used construction RNAi <br />                                                                                      plasmids taken GeneDB accession nos. Tb10.61.3140 T. brucei <br />                                                                                      GSK-3 short (nucleotides 176 578 construct 1 665 1056 construct <br />    FIG. 1. Enzymatic action GSK-3. With GSK-3 substrates,                    2) Tb927.7.2420 T. brucei long (nucleotides 159 531). The nucleotide <br /> another (priming) kinase places phosphate (PO3) serine               bases primer pairs (primer pairs 1 2, 3 4, 5 6 [Table <br /> threonine (S/T) residue separated amino acids (X)                    1]) amplified T. brucei 927 genomic DNA. The resultant amplicons <br /> carboxy direction target S/T residues. GSK-3 phosphorylates                  ligated use TA cloning vector p2T7TABlue (a gift D. <br /> target S/T groups. Occasionally, GSK-3 shown phosphor-                   Horn, London School Hygiene Tropical Medicine) (2), se- <br /> ylate nonprimed peptide substrates shown autophos-                   quences confirmed nucleotide sequence analysis inserts. The <br /> phorylate GSK-3 S/T tyrosine (10, 32).                                         constructs linearized NotI restriction enzyme (New England Bio- <br />                                                                                      labs, Ipswich, MA). T. brucei bloodstream-form (BSF) parasites (provided by. G. <br />                                                                                      Cross, Rockefeller University) expressing T7 RNA polymerase Tet <br />                                                                                      repressor single selection marker (SM), G418 resistance, cultured <br /> pregnant women infants, GSK-3 regulates proteins                         HMI-9 medium 10% heat-inactivated fetal bovine serum G418 2.5 <br /> critical development, wnt gene product. How-                          &#226;?&#174;g/ml 37&#194;&#176;C 5% CO2 atmosphere (15). Ten micrograms T. brucei GSK-3 <br /> ever, optimization selectivity drug candidates                         linearized p2T7TABlue electroporated mid-log-phase T. brucei <br /> parasite kinases issue highly conserved                        (2.5 &#226;&#171;&#187; 107) suspended 500 &#226;?&#174;l cytomix (120 mM KCl, 0.15 mM CaCl2, 10 <br />                                                                                      mM K2HPO4-KH2PO4, pH 7.6, 25 mM HEPES, 2 mM disodium EDTA, 5 mM <br /> amino acids protein conformation catalytic domains <br />                                                                                      MgCl2). Electroporation 4-mm gap cuvettes 1.6 kV 24 &#226;?&#8364;, as <br /> (5, 18, 25, 26). Understanding differences substrate                      described previously (33). The cells resuspended HMI-9 medium sup- <br /> binding properties three-dimensional structures be-                          plemented 2.5 &#226;?&#174;g/ml hygromycin 2.5 &#226;?&#174;g/ml G418. Stable individual <br /> tween mammalian parasite GSK-3 enzymes important                              clones selected 5 7 days transfection. Selected cultures diluted <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br /> for optimization selected target inhibitors drug de-                      1 &#226;&#171;&#187; 105 cells/ml induced express double-stranded RNA addition 1 <br />                                                                                      &#226;?&#174;g/ml tetracycline. Growth measured cultures passed daily 1:10 to <br /> velopment (6, 18). <br />                                                                                      1:20 dilution monitored ATPLite luminescence ATP detection <br />    In report, RNA interference (RNAi)                             assay (catalog no. 6016941; Perkin-Elmer, Waltham, MA). Cell growth <br /> assay chemical validation T. brucei GSK-3 poten-                       monitored 7 days. <br /> tial drug target treatment African sleeping sickness.                        Northern analysis. RNA isolated induced noninduced cultures <br /> Inhibitor-target interactions, expressed calculated inter-                    48 h growth RNeasy kit (Qiagen, Valencia, CA). Twelve 16 &#226;?&#174;g <br />                                                                                      total RNA electrophoresed formaldehyde gel blotted stan- <br /> action energy, predicted improved using <br />                                                                                      dard procedures (4). The RNA membrane analyzed 32P-labeled <br /> computer modeling software detect binding pockets                             DNA probe complementary GSK-3 mRNA region contained the <br /> present T. brucei GSK-3 absent human ho-                             RNAi constructs. The probe amplified genomic DNA primers 3 <br /> molog enzyme (18).                                                            4 GSK-3 short version 1, primers 1 2 GSK-3 short version 2, and <br />                                                                                      primers 7 8 GSK-3 long (Table 1). <br />                                                                                         DNA-DNA hybridization. Genomic DNA isolated T. brucei brucei <br />                          MATERIALS AND METHODS                                       427 lysis TELT buffer (50 mM Tris HCl, pH 8.0, 62.5 mM EDTA, 2.5 M <br />   Bioinformatics. T. brucei orthologs human GSK-3&#226;?&#163; (UniProt P49840)           LiCl, 49% [vol/vol] Triton X-100), followed phenol-chloroform extraction <br /> human GSK-3&#226;?&#164; (UniProt P49841) identified T. brucei genome             (20), subjected double restriction endonuclease digests. Enzymes in <br /> using BLASTP tool website GeneDB (www. Genedb.org). Amino acid            regions outside gene cut 1,000 bp outside the <br /> sequence identity values determined using ALIGN tool (24)         genes picked. The restricted fragments run 1.0% agarose gel, <br /> Biology Workbench (version 3.2) website (http://segtool.sdsc.edu/CGI/BW.cgi).        visualized staining ethidium bromide, subsequently blotted a <br />   RNAi. The T. brucei GSK-3 homologs, encode long isoform (T.            nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, En- <br /> brucei GSK-3 long) short isoform (T. brucei GSK-3 short) enzyme,        gland) capillary transfer. The membrane probed appropriately <br />                                                                                      32 <br /> respectively, targets knockdown experiment. Two RNAi constructs            P-radiolabeled RNAi region GSK-3 short version 1 gene amplified with <br /> were knock short gene, RNAi construct           primer pairs 1 2 (Table 1). <br />  <br />  <br />  <br />                                                            TABLE 1. Oligonucleotide primers used <br />        Primer use no.                ORF position                Primer designation                                      Sequence (5&#226;&#172;&#732;&#226;&#8364;&#8220;3&#226;&#172;&#732;) <br />  <br /> RNAi <br />  1                                          176&#226;&#8364;&#8220;578              GSKshort1Fwd                        CTGGATCCACCGAGAGTTGCAAATTATG <br />  2                                                               GSKshort1Rev                        AAGGATCCTAGTAACGCGAGCAAATGTA <br />  3                                          665&#226;&#8364;&#8220;1056             GSKshort2Fwd                        GTGGATCCTTCTTGGTGAACCGATATTC <br />  4                                                               GSKshort2Rev                        TTGGATCCCTTCTTCAGCAGATACTCCC <br />  5                                          159&#226;&#8364;&#8220;531              GSKLongFwd                          CCATGCGAGCAAGTGAGGTATG <br />  6                                                               GSKLongRev                          GGCACTGGGATCAGAAGCGAAG <br />  7                                        1013&#226;&#8364;&#8220;1422              GSKLongprobe1a                      CATCTGAGCGGGAACTCTTCG <br />  8                                                               GSKLongprobe2a                      CAGCCACGGTGGTAAAATCTC <br />  <br /> GSK-3 protein expression <br />  9                                            1&#226;&#8364;&#8220;1059             T. brucei GSKLICFwd                 CTCACCACCACCACCACCATATGTCGCTCAACC <br />                                                                                                       TTACCGATGC <br />   10                                                             T. brucei GSKLICRev                 ATCCTATCTTACTCACTTACTTCTTCAGCAGAT <br />                                                                                                       ACTCCCGC <br />   a <br />       Used probes Northern blot analysis T. brucei GSK-3 long. <br />  3712         OJO ET AL.                                                                                                   ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br />   TABLE 2. Comparison amino acid sequence identities the <br />       human orthologs GSK-3 T. brucei GSK-3 <br />                    long GSK-3 short <br />                                               % Identitya <br />         Enzyme               Human             T. brucei          T. brucei <br />                              GSK-3&#226;?&#164;           GSK-3 long         GSK-3 short <br />  <br /> Human GSK-3&#226;?&#163;              67.4 (1e&#226;&#171;&#186;177)     29.7 (2.2 e&#226;&#171;&#186;66)     35.6 (2.7e&#226;&#171;&#186;82) <br /> Human GSK-3&#226;?&#164;                                33.1 (1.0e&#226;&#171;&#186;71)      40.9 (9.1e&#226;&#171;&#186;89) <br /> T. brucei GSK-3 long                                            30.6 (4.6e&#226;&#171;&#186;66) <br />   a <br />       The smallest sum probability BLASTP search shown parentheses. <br />  <br />  <br />  <br />    PCR ligase-independent cloning. Regions T. brucei GSK-3 short <br /> gene open reading frame (ORF) amplified T. brucei brucei 427              FIG. 3. Southern blot T. brucei genomic DNA T. brucei <br /> genomic DNA primers T. brucei GSKLICFwd, T. brucei GSKLICRev             GSK-3 short-specific probe. Genomic T. brucei brucei 427 SM DNA <br /> (primers 9 10, respectively, Table 1). The primer probe sequences used    digested, blotted, probed RNAi region GSK-3 <br /> in study listed Table 1. The PCR product cloned          short 1 (S1) verify single band corresponding T. <br /> maltose-binding protein (MBP)&#226;&#8364;&#8220;AVA0421 fusion vector. MBP-AVA0421             brucei GSK-3 short gene hybridizes T. brucei genome. The <br /> ligase-independent cloning vector expresses proteins N-terminal six-   predicted restriction digest sizes follows: BamHI-PstI, 1,702 bp; <br /> His&#226;&#8364;&#8220;MBP&#226;&#8364;&#8220;3C cleavage site&#226;&#8364;&#8220;ORF fusion. MBP-AVA0421 generated               BamHI-AvaI, 2,214 bp; NcoI-PstI, 2,655 bp; NcoI-AvaI, 3,167 bp. <br />  <br />  <br />  <br />                                                                                   AVA0421 ligating PCR-amplified MBP sequence eight-His&#226;&#8364;&#8220;MBP&#226;&#8364;&#8220; <br />                                                                                   BG1861 NdeI KpnI restrictions sites (1). The inserts the <br />                                                                                   vector double digested NruI PmeI joined ligase- <br />                                                                                   independent cloning, described previously (21). <br />                                                                                      Expression purification T. brucei GSK-3 short version. The expression <br />                                                                                   recombinant protein automatically induced Escherichia coli <br />                                                                                   BL21(DE5)* (Invitrogen, Carlsbad, CA) ZY5052 medium supplemented with <br />                                                                                   100 &#226;?&#174;g/ml ampicillin growth 24 h 20&#194;&#176;C agitation 200 rpm. Cells <br />                                                                                   harvested centrifugation stored &#226;&#171;&#186;80&#194;&#176;C flash <br />                                                                                   frozen liquid nitrogen. The frozen cells resuspended disrupted by <br />                                                                                   sonication 200 ml lysis buffer containing 25 mM HEPES (pH 7.25), 500 mM <br />                                                                                   NaCl, 5% glycerol, 2 mM dithiothreitol (DTT) (standard buffer) 10 mg <br />                                                                                   lysozyme 20 mM imidazole. The cell debris clarified centrifugation, <br />                                                                                   target protein purified clarified cell lysate binding on <br />                                                                                   nitrilotriacetic acid nickel resins (Qiagen) equilibrated standard buffer. The <br />                                                                                   recombinant T. brucei GSK-3 short protein eluted 250 mM imidazole plus <br />                                                                                   1 mM DTT dialyzed standard buffer 1 mM DTT further <br />                                                                                   resolved size-exclusion gel chromatography (Superdex 75 26/60; GE Bio- <br />                                                                                   sciences, Piscataway, NJ). Pure fractions collected single peak analyzed <br />                                                                                   sodium dodecyl sulfate-polyacrylamide gel electrophoresis Bio-Rad gel <br />                                                                                   <span id='am-2' about='Thesaurus:code' typeof='owl:Thing'>code</span> blue staining (see Fig. 4). The enzymes stored &#226;&#171;&#186;20&#194;&#176;C 50% <br />                                                                                   glycerol&#226;&#8364;&#8220;12.5 &#226;?&#174;M HEPES pH 7.5&#226;&#8364;&#8220;250 &#226;?&#174;M NaCl&#226;&#8364;&#8220;0.5 &#226;?&#174;M DTT&#226;&#8364;&#8220;0.0125% sodium <br />                                                                                   azide&#226;&#8364;&#8220;1&#226;&#171;&#187; protease inhibitor (Roche, Indianapolis, IN). <br />                                                                                      Chemical inhibitors. GW8510 (Sigma Chemical Co., St. Louis, MO) (16), <br />                                                                                   SU9516 (Sigma) (22), SB-415286 (Biomol, Plymouth Meeting, PA) (22), cyclin- <br />                                                                                   dependent kinase (CDK) 1 2 inhibitor III (Calbiochem, San Diego, CA) (8), <br />                                                                                   2-cyanoethyl alsterpaullone (Calbiochem) (17) (see Table 3), 43 com- <br />                                                                                   mercially available protein kinase inhibitors (Sigma, Biomol, Calbiochem) <br />                                                                                   included study. In addition, 255-compound GSK-3-focused library <br />                                                                                   collection obtained Merck-Serono (Geneva, Switzerland) evalu- <br />                                                                                   ated. Most Merck-Serono GSK-3 inhibitors 2(Z)-2-[4-tert-butylthia- <br />                                                                                   zol-2(3H)-ylidene]-2-(2-aminopyrimidin-4-yl) acetonitrile core structure with <br />    FIG. 2. RNAi T. brucei GSK-3 homologs. (Top) Growth T.                   modifications (see R1 structures Table 4). <br /> brucei BSF number days tetracycline addition (day 0). T.             Activity assay. Enzyme activity measured scintillation proximity assay <br /> brucei brucei strain 427 SM cells transfected plasmids, which,          (SPA) streptavidin-coated beads, [&#226;?&#165;-33P]ATP (Amersham Biosciences <br /> with tetracycline administration, leads induction double-               Corp., Piscataway, NJ), biotinylated peptide substrate [BioGSP-2; peptide <br /> stranded RNA, resulting RNAi inhibition target gene expression.             sequence biotin-C6-Tyr-Arg-Arg-Ala-Ala-Val-Pro-Pro-Ser-Pro-Ser-Leu-Ser-Ar <br /> Both homologs GSK-3, T. brucei GSK-3 long T. brucei GSK-3                  g-His-Ser-Ser-Pro-His-Gln-Ser(PO3H2)-Glu-Asp-Glu-Glu-Glu; American Pep- <br /> short (two different constructs T. brucei GSK-3 short), sepa-             tide Company, Inc., Sunnyvale, CA]. A filtration assay used measure the <br /> rately targeted, SM cells served no-plasmid controls. With ad-             specific activity GSK-3 Kms ATP peptide substrate <br /> dition tetracycline (&#226;&#171;&#185;), dramatic growth inhibition compared              (BioGSP-2), measured determining level incorporation of <br /> that no-tetracycline control (&#226;&#171;&#186;) occurred long            &#226;?&#165;-33P peptide subsequent binding P-81 filter (Whatman, <br /> or short T. brucei GSK-3 homolog targeted. (Bottom) North-                Florhan Park, NJ). All assays performed buffered solution containing <br /> ern blots showing reduction mRNA levels (Gene) T.                  25 mM Tris-HCl (pH 7.5), 10 mM MgCl2 &#228;&#161;&#160; 6H2O, 5 mM DTT, 0.1 mg/ml bovine <br /> brucei GSK-3 short (S1 S2) T. brucei GSK-3 long (L) tran-                 serum albumin, 2 U/ml heparin incubation 30&#194;&#176;C. The filtration <br /> scripts tetracycline induction (lanes &#226;&#171;&#185;) tetracycline induc-          assay reaction volume 50 &#226;?&#174;l contained 1.2 &#226;?&#174;M BioGSP-2, serially diluted <br /> tion (lanes &#226;&#171;&#186;). The result tubulin mRNA control (Tub) differed              enzyme, unlabeled (1.2 &#226;?&#174;M) &#226;?&#165;-33P-labeled ATP (4 nM); reac- <br /> little RNAi induction tetracycline.                                    tion mixture incubated 60 min. The reactions stopped 100 &#226;?&#174;l <br />  VOL. 52, 2008                                                              GSK-3: DRUG TARGET FOR AFRICAN TRYPANOSOMIASIS                                       3713 <br />  <br />                                                                                     10% trifluoroacetic acid 37.5 mM EDTA 750 &#226;?&#174;M unlabeled ATP. The <br />                                                                                     content reaction mixture spotted P-81 filters, filters were <br />                                                                                     washed times 2.5% phosphoric acid. The SPA used screen for <br />                                                                                     inhibitors determine 50% inhibitory concentrations (IC50s) 303 in- <br />                                                                                     hibitors T. brucei GSK-3 short version Km determined ATP <br />                                                                                     peptide. The mixture used SPA included 20 ng (46.8 nM) of <br />                                                                                     enzyme, 2.4 &#226;?&#174;M peptide substrate, 4.5 &#226;?&#174;M unlabeled ATP, 4 nM &#226;?&#165;-33P- <br />                                                                                     labeled ATP. The reaction mixture incubated 30 min. Quantitative <br />                                                                                     measurement levels phosphate incorporation binding BioGSP-2 <br />                                                                                     T. brucei GSK-3 short enzyme 100 &#226;?&#174;l 20 mg/ml strepta- <br />                                                                                     vidin-coated SPA beads 37.5 mM EDTA&#226;&#8364;&#8220;75 &#226;?&#174;M unlabeled ATP. In each <br />                                                                                     assay, human GSK-3&#226;?&#164; (Upstate Cell Signaling Solutions, Temecula, CA) and <br />                                                                                     assay buffer used positive negative controls, respectively. The emis- <br />                                                                                     sion light SPA bead simulation reaction measured counts per <br />                                                                                     minute Chameleon 425-104 multilabel plate scintillation counter (Hidex; <br />                                                                                     Oy, Turku, Finland). <br />                                                                                        Parasite cultures vitro compound screening assays. BSF T. brucei <br />                                                                                     brucei strain 427 cultured HMI-9 medium supplemented 10% <br />                                                                                     heat-deactivated fetal bovine serum, 1% penicillin, streptomycin 37&#194;&#176;C <br />                                                                                     5% CO2 atmosphere, described previously (15). The vitro suscep- <br />                                                                                     tibilities parasites compounds tested 96-well plates with <br />    FIG. 4. Purity recombinant T. brucei GSK-3 short produced E.               initial inoculum size 1 &#226;&#171;&#187; 105 trypomastigotes well. Compound stock <br /> coli. The enzyme purified metal affinity chromatography, fol-                solutions prepared dimethyl sulfoxide 10 20 mM diluted in <br /> lowed size-exclusion chromatography. Three lanes representing 25                 HMI-9 medium 20 &#226;?&#174;M. They added plates serial <br /> &#226;?&#174;g protein fractions <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span>-size exclusion chromatography (frac- <br />                                                                                     dilutions final volume 200 &#226;?&#174;l/well. The growth triplicate cultures <br /> tions 1 3, respectively) pooled make working batch <br />                                                                                     quantitated 48 h addition Alamar blue (Alamar Bio- <br /> of enzyme study shown. The purity judged be <br />                                                                                     sciences, Sacramento, CA) (28). Pentamidine isethionate (Aventis, Dagen- <br /> greater 98%. <br />  <br />  <br />                           TABLE 3. Commercial kinase inhibitorsa activity GSK enzyme T. brucei BSFs <br />                                                                                                                         IC50 (nM) for <br />                                                                                                                                                                EC50b <br />             Compound                                                    Structure                                       T. brucei GSK <br />                                                                                                                                                                (nM) <br />                                                                                                                            enzyme <br />  <br />  <br />  <br />  <br /> GW8510                                                                                                                           1                              119 <br />  <br />  <br />  <br />  <br /> CDK-1 -2 inhibitor III                                                                                                     13                                 20 <br />  <br />  <br />  <br />  <br /> 2-Cyanoethyl alsterpaullone                                                                                                   336                               150 <br />  <br />  <br />  <br />  <br /> SU9516                                                                                                                        352                               180 <br />  <br />  <br />  <br />  <br /> SB-415286                                                                                                                   1,000                               740 <br />  <br />  <br />  <br />   a <br />       The inhibitors selected panel 48 kinase inhibitors. <br />   b <br />       The EC50s determined T. brucei BSF growth assay. <br />  3714       OJO ET AL.                                                                                                        ANTIMICROB. AGENTS CHEMOTHER. <br />  <br /> ham, United Kingdom) included assay positive control. The              TABLE 4. GSK-3-focused inhibitorsa Merck-Serono with <br /> effective concentration caused 50% growth inhibition (EC50) cal-                activities GSK-3 enzyme T. brucei BSFs <br /> culated nonlinear regression analysis Prism software (Graphpad Soft- <br /> ware, Inc. La Jolla, CA).                                                                                  R1 core structure <br />    Modeling T. brucei GSK-3 homology inhibitor docking. The Protein                                                             IC50 (nM) for <br />                                                                                       Compound                                                                   ED50 <br />                                                                                                                                        T. brucei GSK <br /> Data Bank contains 14 structures human GSK, variations               no.                                                                     (nM)b <br />                                                                                                                                           enzyme <br /> motion hinge domain N- C-terminal lobes enzyme. <br /> For modeling three-dimensional structure T. brucei GSK-3 short <br /> version (Protein Data Bank accession no. 1R0E), human GSK-3 complexed                  1                                                  4                  50 <br /> a 3-indolyl-4-arylmaleimide inhibitor ultimately chosen template be- <br /> cause resulting model led best quantitative structure-activity relation- <br /> ships Merck-Serono inhibitors 2(Z)-2-[4-tert-butylthiazol-              2                                                30                   65 <br /> 2(3H)-ylidene]-2-(2-aminopyrimidin-4-yl) acetonitrile core structure. Creation of <br /> the protein model Homology module INSIGHTII program                         3                                                46                  200 <br /> (Accelrys Software, Inc., San Diego CA) straightforward, insertions <br /> or deletions occurred binding site. Molecular docking inhibitors was <br /> performed Metropolis Monte Carlo procedures FLO/QXP program                     4                                                22                  410 <br /> (19). Inhibitors treated fully flexible, chains amino <br /> acid residues binding site. <br />                                                                                             5                                                30                  458 <br />  <br />  <br />                                   RESULTS                                                   6                                               168                  705 <br />    Sequence analysis RNAi. Two GSK-3-encoding genes <br /> were T. brucei genome BLAST homology                                   a <br />                                                                                            The inhibitors selected panel 255 GSK-3&#226;?&#164; inhibitors. <br /> searches: long version (Tb927.7.2420, encoded pre-                           b <br />                                                                                            The EC50s determined T. brucei BSF growth assay. <br /> dicted 501-amino-acid protein) short version (Tb10.61. <br /> 3140, encoded predicted 352-amino-acid protein). Ho- <br /> mology comparisons did reveal homolog be <br /> equivalent GSK-3&#226;?&#163; GSK-3&#226;?&#164; mammalian form                                 MBP (Fig. 4), non-MBP-fused T. brucei <br /> (Table 2), T. brucei GSK-3 long T. brucei GSK-3                          GSK-3 short enzyme insoluble E. coli. The Km the <br /> short homologous human GSK-3&#226;?&#164; human                               enzyme substrate ATP determined 4.5 &#226;?&#174;M, while <br /> GSK-3&#226;?&#163;. The knockdown T. brucei GSK-3 short long                                Km phosphorylated peptide (GSP-2) 2.4 &#226;?&#174;M. <br /> mRNA accomplished overexpressing double-stranded                               The specific activity purified T. brucei GSK-3 short <br /> RNA mammalian BSFs T. brucei. Two RNAi constructs                               enzyme 1,000 U/mg (where 1 U defined as <br /> were separately tested knock expression T.                         incorporation 1 nM phosphate 1.2 &#226;?&#174;M GSP-2 per <br /> brucei GSK-3 short gene. At 48 h, Northern analysis demon-                            min 30&#194;&#176;C final ATP concentration 1.2 &#226;?&#174;M), is <br /> strated 65% mRNA reduction T. brucei GSK-3 short                                comparable value 922 U/mg cited commercially <br /> construct 1 76% mRNA reduction T. brucei GSK-3                              available human GSK-3&#226;?&#164; (lot 28407U; Upstate Cell Signaling <br /> short construct 2 (Fig. 2). Along reduction T. brucei                     Solutions). <br /> GSK-3 short mRNA, induction double-stranded RNA                                   Activities kinase inhibitors T. brucei GSK-3 short <br /> led striking inhibition cell proliferation (Fig. 2). In-                    construct T. brucei BSF parasites. Screening 48 com- <br /> duction T. brucei GSK-3 long RNAi construct yielded                         mercially available protein kinase inhibitors revealed that <br /> 82% reduction mRNA gene (Fig. 2),                             GW8510 (Table 3) activities 1 nM (IC50) T. <br /> inhibition growth complete produced                          brucei GSK-3 short enzyme 100 nM (EC50) against <br /> the T. brucei GSK-3 short constructs (Fig. 2). Because                         BSFs T. brucei. We identified compounds <br /> more pronounced growth inhibition RNAi directed                            (Table 3) activities enzyme, be <br /> T. brucei GSK-3 short, chose focus work                          inhibiting additional targets T. brucei cells, suggested <br /> T. brucei GSK-3 short enzyme.                                                         comparatively low EC50s comparison IC50s. <br />    Southern blot analysis. Hybridization Southern blot                           In screen 255 compounds known activity against <br /> membrane radiolabeled GSK-3 short-specific probe (the                          human GSK-3&#226;?&#164; (Merck-Serono), observed correlation <br /> same sequence used RNAi) revealed single band                              enzyme cellular activity, supports the <br /> hybridized double restriction enzyme digests rule                        chemical validation T. brucei GSK-3 drug target (ex- <br /> out possible off-target effect RNAi sequence. In                       amples shown Table 4). An excellent correlation be- <br /> case, molecular weight hybridizing band pre-                           tween enzyme inhibition cell growth inhibition dem- <br /> dicted T. brucei GSK-3 short genomic sequence (Fig.                          onstrated compounds series inhibited T. <br /> 3). The presence single band digest mo-                          brucei GSK-3 enzyme T. brucei BSF growth. Further re- <br /> lecular weight predicted T. brucei GSK-3 short indicates                          search required establish &#226;&#8364;&#339;hit&#226;&#8364;? compounds identified <br /> that sequence complementary RNAi                             kill T. brucei cells specifically inhibiting GSK-3 short, the <br /> segment used genome T. brucei, gene                       chemical data support validation GSK-3 short drug <br /> T. brucei GSK-3 short.                                                                target T. brucei. <br />    Expression highly active recombinant T. brucei GSK-3                               Model T. brucei GSK-3 Merck-Serono inhibitors. A <br /> short enzyme. The recombinant T. brucei GSK-3 short con-                              homology model T. brucei GSK-3 short constructed on <br /> struct produced Escherichia coli C-terminal fusion                        basis crystal structure human GSK-3&#226;?&#164; enzyme in <br />  VOL. 52, 2008                                                   GSK-3: DRUG TARGET FOR AFRICAN TRYPANOSOMIASIS                          3715 <br />  <br />  <br />  <br />  <br />    FIG. 5. Correlation experimental (Exp) predicted <br /> (Pred) binding energies (Ebind) use T. brucei GSK-3 short <br /> homology model. R2 0.85; F 23.3, indicates the <br /> linear relationship highly significant 99.0% level. <br />  <br />  <br /> complex inhibitor. Subsequently, Merck-Serono <br /> inhibitors listed Table 4 docked validate model <br /> by determination structure-activity relationship. A linear <br /> regression predicted binding energies exper- <br /> imental energies derived IC50s showed excellent <br /> correlation (R2 &#226;&#171;&#189; 0.85; n &#226;&#171;&#189; 6; F &#226;&#171;&#189; 23.3, indicates                FIG. 6. Model binding mode Merck-Serono inhibitor 2 <br />                                                                         (yellow) T. brucei GSK-3 short (made Pymol; DeLano Scientific <br /> significance level 99.0%) (Fig. 5). The predicted binding            LLC, San Carlos, CA; http://www.pymol.org). <br /> mode 30 nM Merck-Serono inhibitor 2 shown Fig. 6. It <br /> features double hydrogen bond recognition <span id='am-238' about='xsp:pattern' typeof='owl:Thing'>pattern</span> is <br /> typical kinase inhibitors involves 2-amino- <br /> pyrimidinyl group inhibitor consecutive hydrogen           causes specific effect T. brucei GSK-3 short gene <br /> bond donor acceptor protein backbone. Several              expression. This suggests growth-inhibitory effect <br /> hydrophobic contacts present thiazolyl              T. brucei GSK-3 short RNAi occurs independently T. <br /> Cys-170, Phe-31 originating glycine-rich        brucei GSK-3 long inhibition T. brucei GSK-3 short <br /> loop characteristic kinases; nitrile &#226;&#8364;&#339;gatekeeper&#226;&#8364;?       long nonoverlapping functions com- <br /> residue Met-101; pyrimidinyl Leu-159. The N-                plemented another. <br /> methyl-piperidinyl makes hydrogen bond carbonyl                Second, anti-BSF cellular activities activities <br /> Pro-105 enveloped Phe-103 Arg-110,                T. brucei GSK-3 short enzyme series kinase <br /> which salt bridge Glu-106. By comparison            inhibitors directed GSK-3 correlated well. We cannot <br /> human enzyme structure model T. brucei en-               exclude possibility compounds inhibit targets in <br /> zyme structure, predicted specificities           cell GSK-3 exert effects by <br /> GSK-3 kinase inhibitors differences          additive actions. For instance, known GSK-3 <br /> seven residues binding site (Table 5).                           inhibitors inhibit CDK-1 -2 (11, 31), active <br />                                                                         sites similar active site GSK-3 (27). The inhibi- <br />                                                                         tion CDKs shown arrest growth T. brucei <br />                           DISCUSSION <br />                                                                         (12, 13, 31). Recombinant CDK homolog enzymes not <br />    In paper, report genetic chemical validation data        currently available T. brucei difficulty the <br /> that support hypothesis T. brucei GSK-3 short drug        heterologous expression proteins; thus, been <br /> target T. brucei. First, RNAi experiments targeting T. brucei       unable test cross-activities compounds the <br /> GSK-3 short demonstrated dramatic inhibition growth              CDKs. It likely kinase inhibitors act targets <br /> of T. brucei BSFs. It likely RNAi construct inhibits        T. brucei GSK-3 short inhibit BSF cell growth, as <br /> only target T. brucei GSK-3 short gene probing              protein kinase inhibitors effectively impaired cell growth <br /> with DNA fragment used RNAi Southern                   little activity T. brucei GSK-3 short. However, <br /> analysis showed single hybridizing band (in sepa-           strong correlation T. brucei GSK-3 short <br /> rate digests) molecular weight expected T.             enzyme activity BSF cell proliferation inhibition. Thus, the <br /> brucei GSK-3 short gene. Thus, insufficient nucleo-           chemical genetic evidence favors T. brucei GSK-3 short as <br /> tide identity cross hybridization Southern analysis. Fur-        good target drugs, activities <br /> thermore, nucleotide sequence T. brucei GSK-3                T. brucei. <br /> short RNAi construct 47% identity correspond-              The ability selectively target T. brucei GSK-3 enzymes <br /> ing region T. brucei GSK-3 long, stretches nucle-         mammalian GSK-3 orthologs important to <br /> otide identity longer 11 bases, indicating unlikely     avoid toxicity caused effects cell signaling cell <br /> that T. brucei GSK-3 short RNAi affect T. brucei              cycle regulation. Human GSK-3&#226;?&#164; T. brucei GSK-3 short <br /> GSK-3 long expression. Therefore, likely RNAi           41% identical, thus, possible selec- <br />  3716          OJO ET AL.                                                                                                                                ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br />          TABLE 5. Comparison GSK-3 binding site residuesa                                                         M. E. Dumont, E. M. Phizicky, E. J. Grayhack. 2004. A facile method for <br />                                                                                                                      high-throughput co-expression protein pairs. Mol. Cell. Proteomics 3:934&#226;&#8364;&#8220; <br /> T. brucei                                                                                        Human               938. <br />                                                                                                                 2.   Alibu, V. P., L. Storm, S. Haile, C. Clayton, D. Horn. 2005. A doubly <br /> V25 ................................................................................................... V61          inducible RNA interference rapid RNAi plasmid construc- <br /> A26.................................................................................................... I62          tion Trypanosoma brucei. Mol. Biochem. Parasitol. 139:75&#226;&#8364;&#8220;82. <br /> G27 ................................................................................................... G63     3.   Allocco, J. J., R. Donald, T. Zhong, A. Lee, Y. S. Tang, R. C. Hendrickson, <br /> Q28b .................................................................................................. N64b         P. Liberator, B. Nare. 2006. Inhibitors casein kinase 1 block the <br /> G29 ................................................................................................... G65          growth Leishmania major promastigotes vitro. Int. J. Parasitol. 36: <br /> T30 .................................................................................................... S66         1249&#226;&#8364;&#8220;1259. <br /> F31 .................................................................................................... F67    4.   Barbu, V., F. Dautry. 1989. Northern blot normalization 28S <br />                                                                                                                      rRNA oligonucleotide probe. Nucleic Acids Res. 17:7115. <br /> V34 ................................................................................................... V70 <br />                                                                                                                 5.   Copeland, R. A., D. L. Pompliano, T. D. Meek. 2006. Drug-target <br /> L36 .................................................................................................... Q72         residence time implications lead optimization. Nat. Rev. Drug <br /> A47 ................................................................................................... A83          Discov. 5:730&#226;&#8364;&#8220;739. <br /> K49 ................................................................................................... K85     6.   Dajani, R., E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale, L. H. <br /> E 61................................................................................................... E97          Pearl. 2001. Crystal structure glycogen synthase kinase 3 beta: structural <br /> M65................................................................................................... M101          basis phosphate-primed substrate specificity autoinhibition. Cell <br /> V77 ................................................................................................... V110         105:721&#226;&#8364;&#8220;732. <br /> M101................................................................................................. L132      7.   Droucheau, E., A. Primot, V. Thomas, D. Mattei, M. Knockaert, C. Rich- <br /> E102b ................................................................................................ D133b         ardson, P. Sallicandro, P. Alano, A. Jafarshad, B. Baratte, C. Kunick, D. <br />                                                                                                                      Parzy, L. Pearl, C. Doerig, L. Meijer. 2004. Plasmodium falciparum <br /> F103 .................................................................................................. Y134         glycogen synthase kinase-3: molecular model, expression, intracellular local- <br /> V104b ................................................................................................ V135b         isation selective inhibitors. Biochim. Biophys. Acta 1697:181&#226;&#8364;&#8220;196. <br /> P105 .................................................................................................. P136    8.   Eswaran, J., W. H. Lee, J. E. Debreczeni, P. Filippakopoulos, A. Turnbull, O. <br /> E106.................................................................................................. E137          Fedorov, S. W. Deacon, J. R. Peterson, S. Knapp. 2007. Crystal struc- <br /> T107.................................................................................................. T138          tures p21-activated kinases PAK4, PAK5, PAK6 reveal catalytic <br /> H109 ................................................................................................. Y140          domain plasticity active group II PAKs. Structure 15:201&#226;&#8364;&#8220;213. <br /> R110 ................................................................................................. R141     9.   Fairlamb, A. H. 2003. Chemotherapy human African trypanosomiasis: <br /> K154 ................................................................................................. K183          current future prospects. Trends Parasitol. 19:488&#226;&#8364;&#8220;494. <br />                                                                                                                10.   Frame, S., P. Cohen. 2001. GSK3 takes centre stage 20 years <br /> H156 ................................................................................................. Q185          discovery. Biochem. J. 359:1&#226;&#8364;&#8220;16. <br /> N157 ................................................................................................. N186    11.   Grant, K. M., M. H. Dunion, V. Yardley, A. L. Skaltsounis, D. Marko, G. <br /> L159.................................................................................................. L188          Eisenbrand, S. L. Croft, L. Meijer, J. C. Mottram. 2004. Inhibitors of <br /> C170.................................................................................................. C199          Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library <br /> D171 ................................................................................................. D200          screen antileishmanial activity. Antimicrob. Agents Chemother. <br />                                                                                                                      48:3033&#226;&#8364;&#8220;3042. <br />   a <br />       The different pairs shown boldface.                                                               12.   Hammarton, T. C., J. Clark, F. Douglas, M. Boshart, J. C. Mottram. <br />   b <br />       Only backbone binding site.                                                                      2003. Stage-specific differences cell cycle control Trypanosoma brucei <br />                                                                                                                      revealed RNA interference mitotic cyclin. J. Biol. Chem. 278:22877&#226;&#8364;&#8220; <br />                                                                                                                      22886. <br />                                                                                                                13.   Hammarton, T. C., M. Engstler, J. C. Mottram. 2004. The Trypanosoma <br /> tive inhibitors T. brucei GSK-3 short found. Indeed,                                                       brucei cyclin, CYC2, required cell cycle progression G1 phase <br /> the molecular modeling studies differences active                                                        maintenance procyclic form cell morphology. J. Biol. Chem. <br />                                                                                                                      279:24757&#226;&#8364;&#8220;24764. <br /> sites able translated development                                                14.   Hammarton, T. C., J. C. Mottram, C. Doerig. 2003. The cell cycle of <br /> of selective inhibitors. An example potential selectivity                                                    parasitic protozoa: potential chemotherapeutic exploitation. Prog. Cell <br /> this study interactions Merck-Serono                                                       Cycle Res. 5:91&#226;&#8364;&#8220;101. <br />                                                                                                                15.   Hirumi, H., K. Hirumi. 1989. Continuous cultivation Trypanosoma <br /> inhibitors predicted Met-101 T. brucei GSK-3                                                       brucei blood stream forms medium containing low concentration of <br /> short, Leu human GSK-3&#226;?&#164;. We pursuing                                                               serum protein feeder cell layers. J. Parasitol. 75:985&#226;&#8364;&#8220;989. <br /> determination crystallographic structures T. brucei                                                  16.   Johnson, K., L. Liu, N. Majdzadeh, C. Chavez, P. C. Chin, B. Morrison, L. <br />                                                                                                                      Wang, J. Park, P. Chugh, H. M. Chen, S. R. D&#226;&#8364;&#8482;Mello. 2005. Inhibition of <br /> GSK-3 short complexed inhibitors; difficult                                                     neuronal apoptosis cyclin-dependent kinase inhibitor GW8510: iden- <br /> to cleave MBP T. brucei GSK-3 short, separate nonphos-                                                          tification 3&#226;&#172;&#732; substituted indolones scaffold development of <br />                                                                                                                      neuroprotective drugs. J. Neurochem. 93:538&#226;&#8364;&#8220;548. <br /> phorylated phosphorylated proteins, sufficient <br />                                                                                                                17.   Kunick, C., Z. Zeng, R. Gussio, D. Zaharevitz, M. Leost, F. Totzke, C. <br /> protein crystallization trials. Future studies include                                                      Scha &#194;&#168;chtele, M. H. G. Kubbutat, L. Meijer, T. Lemcke. 2005. Structure- <br /> continued attempts solve three-dimensional structure                                                       aided optimization kinase inhibitors derived alsterpaullone. Chem- <br />                                                                                                                      biochem 6:541&#226;&#8364;&#8220;549. <br /> well perform high-throughput screening inhibitors                                                 18.   Liao, J. J. 2007. Molecular recognition protein kinase binding pockets for <br /> against T. brucei GSK-3 short human GSK-3&#226;?&#164;                                                               design potent selective kinase inhibitors. J. Med. Chem. 50:409&#226;&#8364;&#8220;424. <br /> compounds selectivity T. brucei GSK-3 short.                                                     19.   McMartin, C., R. S. Bohacek. 1997. QXP: powerful, rapid computer <br />                                                                                                                      algorithms structure-based drug design. J. Comput. Aided Mol. Des. <br />                                                                                                                      11:333&#226;&#8364;&#8220;344. <br />                                  ACKNOWLEDGMENTS                                                               20.   Medina-Acosta, E., G. A. Cross. 1993. Rapid isolation DNA from <br />                                                                                                                      trypanosomatid protozoa using simple &#226;&#8364;&#732;mini-prep&#226;&#8364;&#8482; procedure. Mol. Bio- <br />   We acknowledge key collaborations initiated Solomon Nwaka                                                   chem. Parasitol. 59:327&#226;&#8364;&#8220;329. <br /> of UNICEF/UNDP/World Bank/WHO Special Programme Re-                                                        21.   Mehlin, C., E. Boni, F. S. Buckner, L. Engel, T. Feist, M. H. Gelb, L. Haji, <br /> search Training Tropical Diseases, continues advise                                                 D. Kim, C. Liu, N. Mueller, P. J. Myler, J. T. Reddy, J. N. Sampson, E. <br /> on project. We acknowledge support Wim Hol                                                   Subramanian, W. C. Van Voorhis, E. Worthey, F. Zucker, W. G. Hol. <br /> entire Medical Structural Genomics Pathogenic Protozoa group,                                                     2006. Heterologous expression proteins Plasmodium falciparum: <br /> who initiated cloning characterization T. brucei GSK-3                                                    results 1000 genes. Mol. Biochem. Parasitol. 148:144&#226;&#8364;&#8220;160. <br /> short.                                                                                                         22.   Meijer, L., M. Flajolet, P. Greengard. 2004. Pharmacological inhibitors <br />   Funding study UNICEF/UNDP/World Bank/                                                            glycogen synthase kinase 3. Trends Pharmacol. Sci. 25:471&#226;&#8364;&#8220;480. <br />                                                                                                                23.   Naula, C., M. Parsons, J. C. Mottram. 2005. Protein kinases drug <br /> WHO Special Programme Research Training Tropical Dis-                                                     targets trypanosomes Leishmania. Biochim. Biophys. Acta 1754:151&#226;&#8364;&#8220; <br /> eases unrestricted grant Merck-Serono.                                                                   159. <br />                                                                                                                24.   Pearson, W. R., D. J. Lipman. 1988. Improved tools biological <br />                                            REFERENCES                                                                sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444&#226;&#8364;&#8220;2448. <br />  1. Alexandrov, A., M. Vignali, D. J. LaCount, E. Quartley, C. Vries, D. De                                 25.   Pink, R., A. Hudson, M. A. Mouries, M. Bendig. 2005. Opportunities and <br />     Rosa, J. Babulski, S. F. Mitchell, L. W. Schoenfeld, S. Fields, W. G. Hol,                                       challenges antiparasitic drug discovery. Nat. Rev. Drug Discov. 4:727&#226;&#8364;&#8220;740. <br />  VOL. 52, 2008                                                               GSK-3: DRUG TARGET FOR AFRICAN TRYPANOSOMIASIS                                     3717 <br />  <br /> 26. Plyte, S. E., K. Hughes, E. Nikolakaki, B. J. Pulverer, J. R. Woodgett.         synthase kinase-3 beta intact cells serine 9 phosphorylation. Biochem. <br />     1992. Glycogen synthase kinase-3: functions oncogenesis develop-             J. 303:701&#226;&#8364;&#8220;704. <br />     ment. Biochim. Biophys. Acta 1114:147&#226;&#8364;&#8220;162.                                      31. Tu, X., C. C. Wang. 2005. Pairwise knockdowns cdc2-related kinases <br /> 27. Polychronopoulos <br /> </body></html>